scholarly journals A study towards drug discovery for the management of type 2 diabetes mellitus through inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by chalcone derivatives

2019 ◽  
Vol 10 (9) ◽  
pp. 5510-5520 ◽  
Author(s):  
Sónia Rocha ◽  
Adelaide Sousa ◽  
Daniela Ribeiro ◽  
Catarina M. Correia ◽  
Vera L. M. Silva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Discovery ◽  
Competitive Inhibitor ◽  
Therapeutic Drug ◽  
Chalcone Derivatives ◽  
Hydrolyzing Enzymes

Butein, a competitive inhibitor of α-amylase and α-glucosidase enzymes, is a promising therapeutic drug to modulate diabetes mellitus.

scholarly journals Correction: A study towards drug discovery for the management of type 2 diabetes mellitus through inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by chalcone derivatives

2019 ◽  
Vol 10 (9) ◽  
pp. 6203-6203 ◽  
Author(s):  
Sónia Rocha ◽  
Adelaide Sousa ◽  
Daniela Ribeiro ◽  
Catarina M. Correia ◽  
Vera L. M. Silva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Discovery ◽  
Chalcone Derivatives ◽  
Hydrolyzing Enzymes

Correction for ‘A study towards drug discovery for the management of type 2 diabetes mellitus through inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by chalcone derivatives’ by Sónia Rocha, et al., Food Funct., 2019, DOI: 10.1039/c9fo01298b.

Exploration of SQC Formula Effect on Type 2 Diabetes Mellitus by Whole Transcriptome Profile in Rats

2021 ◽  
Vol 21 ◽  
Author(s):  
Xiaoxu Fu ◽  
Xiujuan Zhou ◽  
Ya Liu ◽  
Yuanhong Lei ◽  
Hongyan Xie ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Rat ◽  
Therapeutic Drug ◽  
Chemical Stimulus ◽  
Gene Microarray ◽  
Curative Effect ◽  
Microarray Experiments

Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that has turned up as dimensions of the pandemic all over the world. In China, some traditional Chinese herbal formulas have enjoyed a high reputation in T2DM treatment for centuries. Methods: In this study, ShenQi compound (SQC) is proposed, a formula has been performed on T2DM clinical therapeutics in China for many years. The efficacy of SQC in diabetic rat model by measuring food and water intake and examining islet microcirculatory index involves islets microvessel quantity and density, islets size, pancreatic microvascular wall thickness is evaluated. Meanwhile, gene microarray experiments were performed to explore the molecular mechanism of SQC treatment. In addition, a western medicine, metformin was employed as a comparison. Results: The results indicated that SQC could effectively improve polydipsia, polyphagia and weight loss caused by diabetes as well as pancreatic tissue damage and vascular injury for T2DM. Meanwhile, the gene microarray experiments indicated that SQC may improve the T2DM through affecting the biological functions related to detection of chemical stimulus involved in sensory perception of smell, G-protein coupled receptor signaling pathway, cytoplasmic translation. In addition, SQC presented curative effect by regulated function associated with translation, while metformin presented curative effect by regulated function associated coagulation. Conclusion: SQC is an effective therapeutic drug on T2DM, and present curative effect by regulated function associated with translation.

Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus

2021 ◽  
Vol 23 ◽  
pp. 100329
Author(s):  
Prateek Sharma ◽  
Sukhbir Singh ◽  
Vinay Thakur ◽  
Neelam Sharma ◽  
Ajmer Singh Grewal
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Targets ◽  
Therapeutic Drug

scholarly journals Evaluation of the Inhibition of Carbohydrate Hydrolyzing Enzymes, the Antioxidant Activity, and the Polyphenolic Content ofCitrus limettaPeel Extract

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Eduardo Padilla-Camberos ◽  
Estefania Lazcano-Díaz ◽  
José Miguel Flores-Fernandez ◽  
Moses S. Owolabi ◽  
Kirk Allen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Antioxidant Activity ◽  
Type 2 Diabetes Mellitus ◽  
Antioxidant Activities ◽  
Chronic Hyperglycemia ◽  
Hydrolyzing Enzymes ◽  
Dose Dependent ◽  
Citrus Limetta

Type 2 diabetes mellitus is one of the most frequent causes of death in Mexico, characterized by chronic hyperglycemia. One alternative strategy for this metabolic abnormality is inhibiting the enzymes responsible for the metabolism of carbohydrates. We evaluated whether the aqueousCitrus limettapeel extract could inhibit the metabolism of carbohydrates. We found that this extract inhibited primarily the enzymeα-amylase by 49.6% at a concentration of 20 mg/mL and to a lesser extent the enzymeα-glucosidase with an inhibition of 28.2% at the same concentration. This inhibition is likely due to the high polyphenol content in theCitrus limettapeel (19.1 mg GAE/g). Antioxidant activity of theCitrus limettapeel demonstrated dose-dependent antioxidant activity, varying from 6.5% at 1.125 mg/mL to 42.5% at 20 mg/mL. The study of these polyphenolic compounds having both antihyperglycemic and antioxidant activities may provide a new approach to the management of type 2 diabetes mellitus.

scholarly journals GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery

2021 ◽  
Vol 64 (8) ◽  
pp. 4312-4332
Author(s):  
Gabriele Carullo ◽  
Sarah Mazzotta ◽  
Margarita Vega-Holm ◽  
Fernando Iglesias-Guerra ◽  
José Manuel Vega-Pérez ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Discovery
Sign in / Sign up

Export Citation Format

Share Document